

Ashish Bhatt,<sup>a\*</sup> Rajesh K. Singh,<sup>b</sup> and Ravi Kant<sup>a</sup>

<sup>a</sup>Department of Chemistry, Mewar university, Chittorgarh, Rajasthan 312901, India


<sup>b</sup>Department of Pharmacy, Mewar university, Chittorgarh, Rajasthan 312901, India

\*E-mail: itsbhatt2007@yahoo.co.in

Received August 5, 2018

DOI 10.1002/jhet.3451

Published online 00 Month 2019 in Wiley Online Library (wileyonlinelibrary.com).



A facile one-pot synthesis of *N*-fused 1,2,4-triazoles from heterocyclic hydrazines and aldehydes is reported. The reaction is efficiently promoted by trichloroisocyanuric acid to afford the desired products mostly in high yields and in relatively short time. The mild nature of the synthesis and short reaction time are notable advantages of the developed protocol. This protocol is effective toward various substrates having different functionalities.

*J. Heterocyclic Chem.*, **00**, 00 (2019).

## INTRODUCTION

Fused aromatic heterocycles are among the most important compound classes in drug discovery and also play a pivotal role in living organisms [1,2]. In particular, such scaffolds can be found as building blocks for DNA (guanine and adenine) and also in many approved drugs, including sildenafil, zolpidem, and trazodone, and in medicinal chemistry studies [3–6] (i.e., tyrosine kinase *c*-Src inhibitors [7,8] or P38 $\alpha$  inhibitors [8]) (Fig. 1).

1,2,4-Triazoles have elicited considerable interest among medicinal chemists because they are considered to be privileged structural constituents of many pharmaceutical agents and natural products [9,10]. In particular, compounds containing *N*-fused 1,2,4-triazoles, such as triazolopyridine and triazolopyrazine substructures, exhibit a wide spectrum of biological activity including antifungal [11], antimicrobial [12], antiviral [13], anti-inflammatory [14], antiasthmatic [15], antiproliferative [16], and hypotonic [17]. In addition, they have often been used as bioisosteres of esters and amides and as dipeptidomimetics in a number of pharmacologically important molecules [18]. On the other hand, they also play important roles as ligands in organometallic compounds, as precursors for *N*-heterocyclic carbenes, as ionic liquids and as corrosion inhibitors [19].

Due to their importance, many efficient methods have been developed to access *N*-fused 1,2,4-triazoles [20]. Among them, coupling of carboxylic acids or their derivatives with amidrazones, followed by cyclodehydration is the most common explored strategy (Scheme 1) [21]. However,


some of these protocols suffer from the limitations of harsh conditions, tedious synthetic procedures, time taking reactions, and unsatisfactory yields. Hence, the development of milder and more general procedures to access *N*-fused 1,2,4-triazoles with high yields in short reaction time remains desirable.

The described oxidative cyclization has previously been reported for the preparation of triazoloquinoxalines [22–28]. Other methods reported in the literature for the cyclization of the triazole ring usually require a combination of *N*-bromosuccinimide and base [29], refluxing orthoesters [30,31], acids [31,32], desulfurization of thiosemicarbazides [33], or cyclization of hydrazides in polyphosphoric acid [31]. A couple of examples of oxidative cyclizations using chloramine-T have previously been reported [34].

Trichloroisocyanuric acid (TCCA) is a versatile reagent and is becoming increasingly popular because of its commercial availability at low cost and lesser corrosiveness. Our continued interest in the development of useful synthetic methodologies prompted us to explore the feasibility of TCCA for the one-pot synthesis of *N*-fused 1,2,4-triazoles with high yields. However, it has not been investigated as a catalyst in the synthesis of 1,2,4-triazoles until now.


## RESULT AND DISCUSSION

Our preliminary investigation began with the reaction of 2-hydrazinopyridine (**1a**) and benzaldehyde (**2a**) in the presence of TCCA (0.3 eq.) in methanol at ambient



**Figure 1.** Representative bioactive molecules comprising fused heterocycles related to 1,2,4-triazoles

**Scheme 1.** General synthesis of *N*-fused 1,2,4-triazoles.




temperature. We were delighted to observe the formation of the desired product (**3a**), albeit in a low yield of 71% (Table 1, entry 1). Next, we optimized the reaction conditions in order to increase the yield. Thus, different solvents were screened, and the results are summarized in Table 1. It was found that ethanol was the most superior solvent in terms of the reaction time and yield of the product (Table 1, entry 2). Once we had established a suitable solvent for the synthesis of *N*-fused 1,2,4-triazoles, we then focused on the quantity of TCCA. An increase in the amount of TCCA (from 0.3 to 1 eq.) not only decreased the reaction time from 1 h to 10 min but


also increased the product yield from 80% to 95% (Table 1, entry 8). Further increasing the quantity of TCCA (from 1 to 2 eq.) led to a decrease in the yield to 81% (Table 1, entry 9). Therefore, we decided to perform the subsequent reactions of the heterocyclic hydrazines with different aldehydes in the presence of TCCA (1 eq.) in ethanol at ambient temperature. The progress of the reactions was monitored by thin-layer chromatography (TLC) analysis using EtOAc/hexane as the eluent.

With optimized conditions in hand, the scope of the reaction was investigated and the results are summarized in Table 2. As expected, all of the aldehydes employed gave the corresponding *N*-fused 1,2,4-triazoles in good to excellent yields. Benzaldehydes with electron-donating groups such as *o*-tolualdehyde (**2b**) and *p*-anisaldehyde (**2f**) gave the desired products in very good yields (Table 2, entries 2 and 6). An aromatic aldehyde with an electronwithdrawing group, 3-trifluoromethyl

**Table 1**  
Optimization of the reaction conditions.




Entry	Solvent	TCCA (eq.)	Time	Yield (%)
1	MeOH	0.3	1 h	71
2	EtOH	0.3	45 min.	80
3	MeCN	0.3	1.5 h	50
4	Toluene	0.3	1.5 h	60
5	AcOH	0.3	1 h	65
7	EtOH	0.5	30 min.	90
8	EtOH	1	10 min.	95
9	EtOH	2	5 min.	81








**Table 2**Synthesis of various [1,2,4]triazolo[4,3-*a*]pyridines, [1,2,4]triazolo[4,3-*a*]pyrazines, and [1,2,4]triazolo[4,3-*a*]pyrimidines.

Entry	Het/Ar	Product	Time (min)	Yield (%)
1	Ph <b>2a</b>		10	95
2	2-MeC <sub>6</sub> H <sub>4</sub> <b>2b</b>		10	98
3	3-CF <sub>3</sub> C <sub>6</sub> H <sub>4</sub> <b>2c</b>		15	85
4	4-ClC <sub>6</sub> H <sub>4</sub> <b>2d</b>		15	90
5	4-BrC <sub>6</sub> H <sub>4</sub> <b>2e</b>		15	91
6	4-OMeC <sub>6</sub> H <sub>4</sub> <b>2f</b>		10	98
7	4-OHC <sub>6</sub> H <sub>4</sub> <b>2g</b>		10	90

(Continues)

**Table 2**  
(Continued)



Entry	Het/Ar	Product	Time (min)	Yield (%)
8	4-CNC <sub>6</sub> H <sub>4</sub> <b>2h</b>		10	85
9	4-Me thiazolyl <b>2i</b>		15	80
10	2-furyl <b>2j</b>		15	88
11	3-indolyl <b>2k</b>		20	82
12	Ph <b>2a</b>		10	92
13	Ph <b>2a</b>		10	90
14	Ph <b>2a</b>		10	86

benzaldehyde (**2c**), 4-chlorobenzaldehyde (**2d**), and 4-bromobenzaldehyde (**2e**) gave the corresponding triazole in 85% (**3c**), 90% (**3d**), and 91% (**3e**) yield, respectively

(Table 2, entries 3, 4, and 5). The heteroaryl aldehyde, 5-formyl thiazole (**2i**), 2-formylfuran (**2j**), and 3-formyl indole (**2k**) reacted smoothly, affording the corresponding

desired products (**3i**), (**3j**), and (**3k**) in good yield (Table 2, entries 9, 10, and 11). Pyrazine, pyridazine, and pyrimidine have also been successfully cyclized with aldehydes affording the corresponding valuable cyclized products (**3l**), (**3m**), and (**3n**) in good yields.

## CONCLUSION

In conclusion, we have developed a short and efficient synthesis of *N*-fused 1,2,4-triazoles using a mild and straightforward one-pot oxidative cyclization method using TCCA which is a low cost commercially available reagent. A variety of substituents are tolerated allowing the synthesis of diverse products in good to excellent yields. The main advantage of this procedure is to access *N*-fused 1,2,4-triazoles with high yields and short reaction time. The newly developed synthetic route is believed to be valuable for the construction of building blocks and also for medicinal chemistry studies comprising *N*-fused 1,2,4-triazole moiety.

## EXPERIMENTAL

**General.** All solvents and reagents were purchased from commercial sources and used without further purification. Melting points were determined on a Stuart SMP3 melting point apparatus without corrections. <sup>1</sup>H-NMR and <sup>13</sup>C-NMR spectra were recorded on AV-500 Bruker using the solvents indicated with 500 and 126 MHz, respectively. Elemental analyses were performed with a VarioEL analyzer. Liquid chromatography mass spectra were obtained on a Waters ACQUITY LCMS/Exvo G2QTof instrument. TLC was performed on silica gel 60 F254 (Merck) TLC plates using hexane/EtOAc (3:2 v/v) as the mobile phase. Column chromatography was carried out using Merck silica gel (200–300 mesh) and hexane/EtOAc (3:2 v/v) as the eluent.

**General procedure for the one-pot synthesis of *N*-fused 1,2,4-triazole 3a–n.** To a stirred solution of heterocyclic hydrazine **1** (1 mmol) and aldehyde **2** (1.2 mmol) in Ethanol (10 mL) were added TCCA (232.41 mg, 1 mmol). The mixture was stirred at ambient temperature until the starting material was completely consumed (monitored by TLC, 10 min.). The reaction mixture was quenched with sat. NaHCO<sub>3</sub> solution (20 mL) and extracted with ethyl acetate (50 mL). The organic layer was washed with water (40 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, and evaporated. The resulting crude compound was purified by silica gel column chromatography (EtOAc/hexane, 4:6 v/v), affording the pure *N*-fused 1,2,4-triazole **3**.

**3-Phenyl-[1,2,4]triazolo[4,3-*a*]pyridine (3a).** Off-white solid; yield: 84.9 mg (95%); m.p. 171–173°C; <sup>1</sup>H-NMR (500 MHz, CDCl<sub>3</sub>): δ 8.30 (dt, *J* = 7.0, 1.2 Hz, 1H), 7.88–7.82 (m, 3H), 7.63–7.55 (m, 3H), 7.31 (ddd, *J* = 9.3, 6.5, 1.1 Hz, 1H), 6.89 (td, *J* = 6.8, 1.1 Hz, 1H); <sup>13</sup>C-NMR (126 MHz, CDCl<sub>3</sub>): δ 150.3, 146.8, 130.3, 129.4, 128.3, 127.5, 126.5, 122.7, 116.6, 114.5; LCMS: *m/z* = 196 [M + H]<sup>+</sup>; calcd for C<sub>12</sub>H<sub>9</sub>N<sub>3</sub>: C, 73.83; H, 4.65; N, 21.52. Found: C, 73.80; H, 4.61; N, 21.48.

**3-(*o*-Tolyl)-[1,2,4]triazolo[4,3-*a*]pyridine (3b).** Off-white solid; yield: 93.9 mg (98%); m.p. 148–150°C; <sup>1</sup>H-NMR (500 MHz, CDCl<sub>3</sub>): δ 7.84 (d, *J* = 9.3 Hz, 1H), 7.80 (d, *J* = 7.0 Hz, 1H), 7.51–7.45 (m, 2H), 7.45–7.40 (m, 1H), 7.37 (td, *J* = 7.3, 1.4 Hz, 1H), 7.30 (ddd, *J* = 9.3, 6.5, 1.2 Hz, 1H), 6.84 (td, *J* = 6.7, 1.1 Hz, 1H), 2.27 (s, 3H); <sup>13</sup>C-NMR (126 MHz, CDCl<sub>3</sub>): δ 149.8, 146.3, 138.6, 131.1, 130.5, 130.3, 127.1, 126.3, 125.6, 122.7, 116.6, 113.9, 19.8; LCMS: *m/z* = 210 [M + H]<sup>+</sup>; calcd for C<sub>13</sub>H<sub>11</sub>N<sub>3</sub>: C, 74.62; H, 5.30; N, 20.08. Found: C, 74.59; H, 5.28; N, 20.05.

**3-(3-(Trifluoromethyl)phenyl)-[1,2,4]triazolo[4,3-*a*]pyridine (3c).** Light yellow solid; yield: 102.5 mg (85%); m.p. 154–156°C; <sup>1</sup>H-NMR (500 MHz, CDCl<sub>3</sub>): δ 8.28 (d, *J* = 7.0 Hz, 1H), 8.14 (d, *J* = 1.7 Hz, 1H), 8.11–8.05 (m, 1H), 7.89 (d, *J* = 9.3 Hz, 1H), 7.84 (d, *J* = 7.9 Hz, 1H), 7.76 (t, *J* = 7.8 Hz, 1H), 7.36 (ddd, *J* = 9.3, 6.5, 1.1 Hz, 1H), 6.97 (td, *J* = 6.8, 1.1 Hz, 1H); <sup>13</sup>C-NMR (126 MHz, CDCl<sub>3</sub>): δ 150.7, 145.4, 131.9 (q, *J* (C, F) = 33.1 Hz), 131.3, 130.0, 127.6, 127.5, 126.9 (q, *J* (C, F) = 3.9 Hz), 125.1 (q, *J* (C, F) = 3.9 Hz), 122.3, 117.0, 114.9; LCMS: *m/z* = 264 [M + H]<sup>+</sup>; calcd for C<sub>13</sub>H<sub>8</sub>F<sub>3</sub>N<sub>3</sub>: C, 59.32; H, 3.06; N, 15.96. Found: C, 59.30; H, 3.01; N, 15.93.

**3-(4-Chlorophenyl)-[1,2,4]triazolo[4,3-*a*]pyridine (3d).** Off-white solid; yield: 94.5 mg (90%); m.p. 198–200°C; <sup>1</sup>H-NMR (500 MHz, CDCl<sub>3</sub>): δ 8.25 (dt, *J* = 7.0, 1.2 Hz, 1H), 7.84 (dt, *J* = 9.3, 1.2 Hz, 1H), 7.81–7.76 (m, 2H), 7.60–7.53 (m, 2H), 7.31 (ddd, *J* = 9.3, 6.5, 1.1 Hz, 1H), 6.91 (ddd, *J* = 7.5, 6.6, 1.1 Hz, 1H); <sup>13</sup>C-NMR (126 MHz, CDCl<sub>3</sub>): δ 150.6, 145.8, 136.4, 129.7, 129.5, 127.3, 125.1, 122.4, 116.9, 114.6; LCMS: *m/z* = 230 [M + H]<sup>+</sup>; calcd for C<sub>12</sub>H<sub>8</sub>ClN<sub>3</sub>: C, 62.76; H, 3.51; N, 18.30. Found: C, 62.73; H, 3.47; N, 18.26.

**3-(4-Bromophenyl)-[1,2,4]triazolo[4,3-*a*]pyridine (3e).** White solid; yield: 113.9 mg (91%); m.p. 200–202°C; <sup>1</sup>H-NMR (500 MHz, CDCl<sub>3</sub>): δ 8.26 (d, *J* = 7.1 Hz, 1H), 7.86 (d, *J* = 9.3 Hz, 1H), 7.74 (s, 4H), 7.32 (ddd, *J* = 9.3, 6.5, 1.1 Hz, 1H), 6.92 (ddd, *J* = 7.4, 6.6, 1.1 Hz, 1H); <sup>13</sup>C-NMR (126 MHz, CDCl<sub>3</sub>): δ 150.7, 145.8, 132.6, 129.6, 127.2, 125.6, 124.7, 122.4, 117.0, 114.6; LCMS: *m/z* = 274 [M + H]<sup>+</sup>; calcd for C<sub>12</sub>H<sub>8</sub>BrN<sub>3</sub>: C, 52.58; H, 2.94; N, 15.33. Found: C, 52.55; H, 2.91; N, 15.29.

**3-(4-Methoxyphenyl)-[1,2,4]triazolo[4,3-*a*]pyridine (3f).** Off-white solid; yield: 101.1 mg (98%); m.p. 122–124°C. <sup>1</sup>H-NMR (500 MHz, CDCl<sub>3</sub>): δ 8.23 (dt, *J* = 7.0, 1.2 Hz,

1H), 7.80 (d,  $J = 9.3$  Hz, 1H), 7.77–7.73 (m, 2H), 7.26 (ddd,  $J = 9.3, 6.5, 1.1$  Hz, 1H), 7.09 (d,  $J = 8.7$  Hz, 2H), 6.84 (td,  $J = 6.8, 1.0$  Hz, 1H), 3.89 (s, 3H);  $^{13}\text{C-NMR}$  (126 MHz,  $\text{CDCl}_3$ ):  $\delta$  161.1, 150.4, 146.7, 129.8, 126.9, 122.6, 118.9, 116.8, 114.8, 114.0, 55.5; LCMS:  $m/z = 226$  [M + H] $^+$ ; calcd for  $\text{C}_{13}\text{H}_{11}\text{N}_3\text{O}$ : C, 69.32; H, 4.92; N, 18.66. Found: C, 69.29; H, 4.89; N, 18.62.

**4-([1,2,4]Triazolol[4,3-*a*]pyridin-3-yl)phenol (3g).** White solid; yield: 87.1 mg (90%); m.p. 248–250°C.  $^1\text{H-NMR}$  (500 MHz,  $\text{DMSO-}d_6$ ):  $\delta$  10.03 (s, 1H), 8.48 (dd,  $J = 7.1, 1.2$  Hz, 1H), 7.81 (dd,  $J = 9.3, 1.2$  Hz, 1H), 7.76–7.64 (m, 3H), 7.39 (ddd,  $J = 9.2, 6.5, 1.1$  Hz, 1H), 7.03–6.95 (m, 3H);  $^{13}\text{C-NMR}$  (126 MHz,  $\text{DMSO-}d_6$ ):  $\delta$  159.0, 149.6, 146.2, 129.7, 127.5, 123.8, 117.1, 116.0, 115.6, 114.1; LCMS:  $m/z = 212$  [M + H] $^+$ ; calcd for  $\text{C}_{12}\text{H}_9\text{N}_3\text{O}$ : C, 68.24; H, 4.29; N, 19.89. Found: C, 68.21; H, 4.25; N, 19.87.

**3-(4-Cyanophenyl)-[1,2,4]triazolol[4,3-*a*]pyridine (3h).** White solid; yield: 85.7 mg (85%); m.p. 261–263°C;  $^1\text{H-NMR}$  (500 MHz,  $\text{CDCl}_3$ ):  $\delta$  8.35–8.31 (m, 1H), 8.06–8.01 (m, 2H), 7.90 (dd,  $J = 8.8, 1.8$  Hz, 3H), 7.38 (ddd,  $J = 9.3, 6.6, 1.1$  Hz, 1H), 6.99 (td,  $J = 6.8, 1.1$  Hz, 1H);  $^{13}\text{C-NMR}$  (126 MHz,  $\text{CDCl}_3$ ):  $\delta$  151.0, 145.0, 133.1, 131.1, 128.5, 127.7, 122.3, 118.0, 117.2, 115.1, 113.8; LCMS:  $m/z = 221$  [M + H] $^+$ ; calcd for  $\text{C}_{13}\text{H}_8\text{N}_4$ : C, 70.90; H, 3.66; N, 25.44. Found: C, 70.88; H, 3.62; N, 25.41.

**5-([1,2,4]Triazolol[4,3-*a*]pyridin-3-yl)-4-methylthiazole (3i).** Brown solid; yield: 79.2 mg (80%); m.p. 127–129°C;  $^1\text{H-NMR}$  (500 MHz,  $\text{CDCl}_3$ ):  $\delta$  9.00 (s, 1H), 8.01 (dt,  $J = 6.9, 1.1$  Hz, 1H), 7.89 (dt,  $J = 9.3, 1.2$  Hz, 1H), 7.38 (ddd,  $J = 9.3, 6.5, 1.1$  Hz, 1H), 6.97 (td,  $J = 6.7, 1.0$  Hz, 1H), 2.58 (s, 3H);  $^{13}\text{C-NMR}$  (126 MHz,  $\text{CDCl}_3$ ):  $\delta$  155.7, 154.1, 150.5, 139.2, 127.7, 122.6, 116.9, 115.0, 114.8, 16.6; LCMS:  $m/z = 217$  [M + H] $^+$ ; calcd for  $\text{C}_{10}\text{H}_8\text{N}_4\text{S}$ : C, 55.54; H, 3.73; N, 25.91. Found: C, 55.51; H, 3.71; N, 25.88.

**3-(Furan-2-yl)-[1,2,4]triazolol[4,3-*a*]pyridine (3j).** Light brown solid; yield: 74.6 mg (88%); m.p. 92–94°C;  $^1\text{H-NMR}$  (500 MHz,  $\text{CDCl}_3$ ):  $\delta$  8.75 (d,  $J = 7.1$  Hz, 1H), 7.83 (d,  $J = 9.3$  Hz, 1H), 7.70–7.67 (m, 1H), 7.34–7.26 (m, 2H), 6.94 (td,  $J = 6.8, 1.1$  Hz, 1H), 6.66 (dd,  $J = 3.5, 1.8$  Hz, 1H);  $^{13}\text{C-NMR}$  (126 MHz,  $\text{CDCl}_3$ ):  $\delta$  149.9, 143.6, 143.0, 139.6, 127.5, 124.3, 116.6, 114.6, 112.1, 111.2; LCMS:  $m/z = 186$  [M + H] $^+$ ; calcd for  $\text{C}_{10}\text{H}_7\text{N}_3\text{O}$ : C, 64.86; H, 3.81; N, 22.69. Found: C, 64.82; H, 3.79; N, 22.65.

**3-(1H-Indol-3-yl)-[1,2,4]triazolol[4,3-*a*]pyridine (3k).** Pinkish-white solid; Yield: 88.01 mg (82%); m.p. 244–246°C;  $^1\text{H-NMR}$  (500 MHz,  $\text{DMSO-}d_6$ ):  $\delta$  11.89 (s, 1H), 8.65 (dt,  $J = 7.1, 1.1$  Hz, 1H), 8.26 (d,  $J = 2.8$  Hz, 1H), 8.16 (dd,  $J = 7.8, 1.0$  Hz, 1H), 7.84 (dt,  $J = 9.3, 1.2$  Hz, 1H), 7.55 (dt,  $J = 8.0, 0.9$  Hz, 1H), 7.40 (ddd,  $J = 9.3, 6.5, 1.1$  Hz, 1H), 7.26 (ddd,  $J = 8.1, 7.0, 1.3$  Hz, 1H), 7.19 (ddd,  $J = 8.0, 7.0, 1.1$  Hz, 1H), 7.03 (td,  $J = 6.7,$

1.1 Hz, 1H);  $^{13}\text{C-NMR}$  (126 MHz,  $\text{DMSO-}d_6$ ):  $\delta$  148.8, 142.8, 136.1, 127.1, 125.6, 125.0, 124.3, 122.5, 120.8, 120.3, 115.6, 113.8, 111.9, 101.3; LCMS:  $m/z = 235$  [M + H] $^+$ ; calcd for  $\text{C}_{14}\text{H}_{10}\text{N}_4$ : C, 71.78; H, 4.30; N, 23.92. Found: C, 71.75; H, 4.28; N, 23.89.

**3-phenyl-[1,2,4]triazolol[4,3-*a*]pyrazine (3 l).** Off-white solid; yield: 81.9 mg (92%); m.p. 161–163°C;  $^1\text{H-NMR}$  (500 MHz,  $\text{CDCl}_3$ ):  $\delta$  9.43 (d,  $J = 1.6$  Hz, 1H), 8.23 (dd,  $J = 4.9, 1.7$  Hz, 1H), 7.95 (d,  $J = 4.8$  Hz, 1H), 7.90–7.86 (m, 2H), 7.66–7.61 (m, 3H);  $^{13}\text{C-NMR}$  (126 MHz,  $\text{CDCl}_3$ ):  $\delta$  147.2, 146.0, 145.1, 130.9, 130.4, 129.6, 128.1, 125.6, 115.2; LCMS:  $m/z = 197$  [M + H] $^+$ ; calcd for  $\text{C}_{11}\text{H}_8\text{N}_4$ : C, 67.34; H, 4.11; N, 28.55. Found: C, 67.31; H, 4.09; N, 28.51.

**6-Chloro-3-phenyl-[1,2,4]triazolol[4,3-*b*]pyridazine (3m).** White solid; yield: 71.8 mg (90%); m.p. 197–199°C;  $^1\text{H-NMR}$  (500 MHz,  $\text{CDCl}_3$ ):  $\delta$  8.49–8.45 (m, 2H), 8.17 (d,  $J = 9.6$  Hz, 1H), 7.61–7.54 (m, 3H), 7.17 (d,  $J = 9.6$  Hz, 1H);  $^{13}\text{C-NMR}$  (126 MHz,  $\text{CDCl}_3$ ):  $\delta$  149.4, 148.1, 143.6, 130.7, 128.8, 127.7, 126.6, 125.5, 121.8; LCMS:  $m/z = 231$  [M + H] $^+$ ; calcd for  $\text{C}_{11}\text{H}_7\text{ClN}_4$ : C, 57.28; H, 3.06; N, 24.29. Found: C, 57.25; H, 3.02; N, 24.26.

**3-Phenyl-[1,2,4]triazolol[4,3-*a*]pyrimidine (3n).** White solid; yield: 76.6 mg (86%); m.p. 174–176°C;  $^1\text{H-NMR}$  (500 MHz,  $\text{CDCl}_3$ ):  $\delta$  8.70 (dd,  $J = 3.8, 1.9$  Hz, 1H), 8.64 (dd,  $J = 7.0, 1.9$  Hz, 1H), 7.87–7.81 (m, 2H), 7.64–7.55 (m, 3H), 6.98 (dd,  $J = 7.0, 3.8$  Hz, 1H);  $^{13}\text{C-NMR}$  (126 MHz,  $\text{CDCl}_3$ ):  $\delta$  154.1, 153.9, 145.7, 130.8, 130.7, 129.5, 128.0, 125.9, 110.2; LCMS:  $m/z = 197$  [M + H] $^+$ ; calcd for  $\text{C}_{11}\text{H}_8\text{N}_4$ : C, 67.34; H, 4.11; N, 28.55. Found: C, 67.31; Hs, 4.09; N, 28.52.

**Acknowledgment.** The authors are thankful to Department of Chemistry, Mewar University, Chittorgarh, Rajasthan, for experimental and spectroscopic analysis of synthesized compounds.

## REFERENCES AND NOTES

- [1] Bhatt, A.; Singh, R. K.; Kant, R. *Chem Biol Lett* 2016, 3, 38.
- [2] Bhatt, A.; Singh, R. K.; Kant, R. *Chem Biol Lett* 2017, 4, 73.
- [3] Endo, K.; Deguchi, K.; Matsunaga, H.; Tomaya, K.; Yamada, K. *Bioorg Med Chem* 2014, 22, 3072.
- [4] Nagamatsu, T.; Fujita, T.; Endo, K. *J Chem Soc, Perkin Trans 1* 2000 33.
- [5] Nagamatsu, T.; Yamasaki, H.; Fujita, T.; Endo, K.; Machida, H. *J Chem Soc, Perkin Trans 1* 1999 3117.
- [6] Kobe, B.; Kobe, J.; Smee, D. F.; Jerman-Blazic-Dzonova, B.; Solmajer, T. *Eur J Med Chem* 1992, 27, 259.
- [7] Mukaiyama, H.; Nishimura, T.; Kobayashi, S.; Ozawa, T.; Kamada, N.; Komatsu, Y.; Kikuchi, S.; Oonota, H.; Kusama, H. *Bioorg Med Chem* 2007, 15, 868.
- [8] Ozawa, T.; Tsuji, E.; Ozawa, M.; Handa, C.; Mukaiyama, H.; Nishimura, T.; Kobayashi, S.; Okazaki, K. *Bioorg Med Chem* 2008, 16, 10311.
- [9] Wencheng, X.; Linna, Z.; Yanzhen, Y.; Dezhi, Y.; Guisen, Z. *Chem Biol Lett* 2014, 1, 44.

- [10] Kumar, P.; Achieng, A. O.; Rajendran, V.; Ghosh, P. C.; Singh, B. K.; et al. *Sci Rep* 2017, 7, 6724.
- [11] Collin, X.; Sauleau, A.; Coulon, J. *Bioorg Med Chem Lett* 2003, 13, 2601.
- [12] Papakonstantinou-Garoufalias, S.; Pouli, N.; Marakos, P.; Chytiroglou-Ladas, A. *Farmacoterapia* 2002, 57, 973.
- [13] De Clercq, E. *J Clin Virol* 2004, 30, 115.
- [14] Navidpour, L.; Shadnia, H.; Shafaroodi, H.; Amini, M.; Dehpour, A. R.; Shafiee, A. *Bioorg Med Chem* 2007, 15, 1976.
- [15] Naito, Y.; Akahoshi, F.; Takeda, S.; Okada, T.; Kajii, M.; Nishimura, H.; Sugiura, M.; Fukaya, C.; Kagitani, Y. *J Med Chem* 1996, 39, 3019.
- [16] Saha, A. K.; Liu, L.; Simoneaux, R.; Decorte, B.; Meyer, C.; Skrzat, S.; Breslin, H. J.; Kukla, M. J.; End, D. W. *Bioorg Med Chem Lett* 2005, 15, 5407.
- [17] Hester, J. B. Jr.; Rudzik, A. D.; Kamdar, B. V. *J Med Chem* 1971, 14, 1078.
- [18] Hitotsuyanagi, Y.; Motegi, S.; Fukaya, H.; Takeya, K. *J Org Chem* 2002, 67, 3266.
- [19] Dash, C.; Shaikh, M. M.; Ghosh, P. *J Chem Sci* 2011, 123, 97.
- [20] Holm, S. C.; Straub, B. F. *Org Prep Proced Int* 2011, 43, 319.
- [21] Meanwell, N. A.; Romine, J. L.; Rosenfeld, M. J.; Martin, S. W.; Trehan, A. K.; Wright, J. J. K.; Malley, M. F.; Gougoutas, J. Z.; Brassard, C. L.; Buchanan, J. O.; Federic, M. E.; Fleming, J. S.; Gamberdella, M.; Hartl, K. S.; Zavoico, G. B.; Seiler, S. M. *J Med Chem* 1993, 36, 3884.
- [22] Aggarwal, R.; Sumran, G.; Kumar, R.; Aggarwal, A.; Parkash, V. *Indian J Heterocycl Chem* 2006, 16, 1.
- [23] Hutchinson, J. H.; Seiders, T. J.; Stearns, B. A.; Wang, B.; Scott, J.M.; Truong, Y. P. *H US* 20070173508A1, 2007.
- [24] Jørgensen, M.; Bruun, A. T.; Rasmussen, L. K. *WO* 2013034758A1, 2013.
- [25] Jørgensen, M.; Bruun, A. T.; Rasmussen, L. K.; Larsen, M. *WO*2013034755A1, 2013.
- [26] Kumar, D.; Chandra, S. K.; Dhillon, H.; Rao, V. S.; Varma, R. *S. Green Chem* 2004, 6, 156.
- [27] Dubey, P. K.; Naidu, A.; Kumar, K. S. *Org Chem: Indian J* 2008, 4, 475.
- [28] Aggarwal, R.; Sumran, G. *Synth Commun* 2006, 36, 1873.
- [29] Nitlikar, L. H.; Darandale, S. N.; Shinde, D. B. *Lett Org Chem* 2013, 10, 348.
- [30] Graceffa, R.; Kaller, M.; La, D.; Lopez, P.; Patel, V. F.; Zhong, W. *US*20100120774A1, 2010.
- [31] Kim, D.; Wang, L.; Beconi, M.; Eiermann, G. J.; Fisher, M. H.; He, H.; Hickey, G. J.; Kowalchick, J. E.; Leiting, B.; Lyons, K.; Marsilio, F.; McCann, M. E.; Patel, R. A.; Petrov, A.; Scapin, G.; Patel, S. B.; Roy, R. S.; Wu, J. K.; Wyvratt, M. J.; Zhang, B. B.; Zhu, L.; Thornberry, N. A.; Weber, A. E. *J Med Chem* 2005, 48, 141.
- [32] Guan, L. P.; Zhang, R. P.; Chang, Y.; Gan, X. X. *Asian J Chem* 2013, 25, 3660.
- [33] Comas, H.; Bernardinelli, G.; Swinnen, D. *J Org Chem* 2009, 74, 5553.
- [34] Bourgeois, P.; Cantegril, R.; Chêne, A.; Gelin, J.; Mortier, J.; Moyroud, J. *Synth Comm* 1993, 23, 3195.

## SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of the article.